- Home
- GCTS vs ACRV Comparison
GCTS vs ACRV Comparison
Compare GCTS & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTS
- ACRV
- Stock Information
- Founded
- GCTS 1998
- ACRV 2018
- Country
- GCTS United States
- ACRV United States
- Employees
- GCTS N/A
- ACRV N/A
- Industry
- GCTS Blank Checks
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- GCTS Finance
- ACRV Health Care
- Exchange
- GCTS Nasdaq
- ACRV Nasdaq
- Market Cap
- GCTS 243.2M
- ACRV 247.8M
- IPO Year
- GCTS N/A
- ACRV 2022
- Fundamental
- Price
- GCTS $2.74
- ACRV $8.36
- Analyst Decision
- GCTS Strong Buy
- ACRV Strong Buy
- Analyst Count
- GCTS 1
- ACRV 5
- Target Price
- GCTS $8.00
- ACRV $22.60
- AVG Volume (30 Days)
- GCTS 128.6K
- ACRV 47.8K
- Earning Date
- GCTS 11-14-2024
- ACRV 11-19-2024
- Dividend Yield
- GCTS N/A
- ACRV N/A
- EPS Growth
- GCTS N/A
- ACRV N/A
- EPS
- GCTS N/A
- ACRV N/A
- Revenue
- GCTS $13,398,000.00
- ACRV N/A
- Revenue This Year
- GCTS N/A
- ACRV N/A
- Revenue Next Year
- GCTS $571.35
- ACRV N/A
- P/E Ratio
- GCTS N/A
- ACRV N/A
- Revenue Growth
- GCTS N/A
- ACRV N/A
- 52 Week Low
- GCTS $2.26
- ACRV $3.19
- 52 Week High
- GCTS $56.00
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- GCTS 51.30
- ACRV 55.35
- Support Level
- GCTS $2.65
- ACRV $8.15
- Resistance Level
- GCTS $2.86
- ACRV $8.66
- Average True Range (ATR)
- GCTS 0.18
- ACRV 0.28
- MACD
- GCTS 0.04
- ACRV 0.02
- Stochastic Oscillator
- GCTS 73.33
- ACRV 51.29
About GCTS GCT Semiconductor Holding Inc. Common Stock
GCT Semiconductor Holding Inc. is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.